https://scholars.lib.ntu.edu.tw/handle/123456789/517579
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | Kamm?ller M. | en_US |
dc.contributor.author | TSEN-FANG TSAI | en_US |
dc.contributor.author | Griffiths C.E.M. | en_US |
dc.contributor.author | Kapoor N. | en_US |
dc.contributor.author | Kolattukudy P.E. | en_US |
dc.contributor.author | Brees D. | en_US |
dc.contributor.author | Chibout S.-D. | en_US |
dc.contributor.author | Safi J. | en_US |
dc.contributor.author | Jr. | en_US |
dc.contributor.author | Fox T. | en_US |
dc.creator | Kamm?Ller M.;Tsen-Fang Tsai;Griffiths C.E.M.;Kapoor N.;Kolattukudy P.E.;Brees D.;Chibout S.-D.;Safi J.;Jr.;Fox T. | - |
dc.date.accessioned | 2020-10-22T07:27:50Z | - |
dc.date.available | 2020-10-22T07:27:50Z | - |
dc.date.issued | 2017 | - |
dc.identifier.issn | 2050-0068 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85033240996&doi=10.1038%2fcti.2017.34&partnerID=40&md5=abba9e4d45c89e2f9fa5f9116aa0b945 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/517579 | - |
dc.description.abstract | Secukinumab, a fully human monoclonal antibody that selectively neutralizes interleukin-17A (IL-17A), has been shown to have significant efficacy in the treatment of moderate to severe psoriasis, psoriatic arthritis and ankylosing spondylitis. Blocking critical mediators of immunity may carry a risk of increased opportunistic infections. Here we present clinical and in vitro findings examining the effect of secukinumab on Mycobacterium tuberculosis infection. We re-assessed the effect of secukinumab on the incidence of acute tuberculosis (TB) and reactivation of latent TB infection (LTBI) in pooled safety data from five randomized, double-blind, placebo-controlled, phase 3 clinical trials in subjects with moderate to severe plaque psoriasis. No cases of TB were observed after 1 year. Importantly, in subjects with a history of pulmonary TB (but negative for interferon-γ release and receiving no anti-TB medication) or positive for latent TB (screened by interferon-γ release assay and receiving anti-TB medication), no cases of active TB were reported. Moreover, an in vitro study examined the effect of the anti-tumor necrosis factor-α (TNFα) antibody adalimumab and secukinumab on dormant M. tuberculosis H37Rv in a novel human three-dimensional microgranuloma model. Auramine-O, Nile red staining and rifampicin resistance of M. tuberculosis were measured. In vitro, anti-TNFα treatment showed increased staining for Auramine-O, decreased Nile red staining and decreased rifampicin resistance, indicative of mycobacterial reactivation. In contrast, secukinumab treatment was comparable to control indicating a lack of effect on M. tuberculosis dormancy. To date, clinical and preclinical investigations with secukinumab found no evidence of increased M. tuberculosis infections. ? The Author(s) 2017. | - |
dc.publisher | Nature Publishing Group | - |
dc.relation.ispartof | Clinical and Translational Immunology | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | adalimumab; alanine aminotransferase; aspartate aminotransferase; bilirubin; gamma interferon; isoniazid; liver enzyme; rifampicin; secukinumab; alanine aminotransferase blood level; antibiotic resistance; Article; aspartate aminotransferase blood level; bilirubin blood level; chemoprophylaxis; colony forming unit; combination drug therapy; comparative study; controlled study; double blind procedure; drug effect; drug safety; enzyme blood level; human; human cell; hypertransaminasemia; in vitro study; incidence; interferon gamma release assay; latent tuberculosis; lung tuberculosis; major clinical study; medical history; observational study; phase 3 clinical trial (topic); priority journal; Psoriasis Area and Severity Index; psoriasis vulgaris; randomized controlled trial (topic); recurrent infection; retrospective study; side effect; staining | - |
dc.title | Inhibition of IL-17A by secukinumab shows no evidence of increased Mycobacterium tuberculosis infections | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1038/cti.2017.34 | - |
dc.identifier.scopus | 2-s2.0-85033240996 | - |
dc.relation.pages | e152 | - |
dc.relation.journalvolume | 6 | - |
dc.relation.journalissue | 8 | - |
item.cerifentitytype | Publications | - |
item.fulltext | no fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.openairetype | journal article | - |
item.grantfulltext | none | - |
crisitem.author.dept | Dermatology | - |
crisitem.author.dept | Dermatology-NTUH | - |
crisitem.author.orcid | 0000-0002-1498-1474 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。